✦ LIBER ✦

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

✍ Scribed by Lievre, A.; Bachet, J.-B.; Boige, V.; Cayre, A.; Le Corre, D.; Buc, E.; Ychou, M.; Bouche, O.; Landi, B.; Louvet, C.; Andre, T.; Bibeau, F.; Diebold, M.-D.; Rougier, P.; Ducreux, M.; Tomasic, G.; Emile, J.-F.; Penault-Llorca, F.; Laurent-Puig, P.

Book ID: 125844249
Publisher: American Society of Clinical Oncology
Year: 2008
Tongue: English
Weight: 148 KB
Volume: 26
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2007.12.5906

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of KRAS p.G13D Mutation in Pat

Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab

✍ Gajate, Pablo; Sastre, Javier; Bando, Inmaculada; Alonso, Teresa; Cillero, Lourd 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 319 KB

Predictive and prognostic value of KRAS

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

✍ Li-Xin Qiu; Chen Mao; Jian Zhang; Xiao-Dong Zhu; Ru-Yan Liao; Kai Xue; Jin Li; Q 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 154 KB

EGFR gene gain and PTEN protein expressi

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

✍ Razis, Evangelia; Pentheroudakis, George; Rigakos, George; Bobos, Mattheos; Kouv 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 596 KB

Distribution of KRAS and BRAF mutations

Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer

✍ Marchoudi, N.; Amrani Hassani Joutei, H.; Jouali, F.; Fekkak, J.; Rhaissi, H. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 294 KB

The Prognostic Role of Ephrin A2 and End

The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

✍ Strimpakos, Alexios; Pentheroudakis, George; Kotoula, Vassiliki; De Roock, Wendy 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 609 KB

Serum matrilysin correlates with poor su

Serum matrilysin correlates with poor survival independently ofKRASandBRAFstatus in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab

✍ Xabier Garcia-Albeniz; Carles Pericay; Virginia Alonso-Espinaco; Vicente Alonso; 📂 Article 📅 2010 🏛 S. Karger AG 🌐 English ⚖ 194 KB